The recently announced grants from the Fall 2022 funding round went to faculty members in medicine, nursing and pharmacy.

“This outstanding result reflects the high calibre of our health researchers,” said UM Vice-President (Research and International) Dr. Mario Pinto.

“This funding will enable UM laboratory scientists to advance knowledge in areas such as cardiovascular health, spinal cord injury, rheumatoid arthritis, asthma, amyotrophic lateral sclerosis and Rett syndrome. Rady Faculty investigators will also conduct cutting-edge data research, as well as vital studies aimed at supporting mental health and well-being.”

The largest grant of more than $1.4 million went to a team led by Dr. Linda Larcombe, an associate professor of internal medicine, community health sciences and medical microbiology/infectious diseases.

Larcombe is an anthropologist whose research focuses on First Nations history, health and collaborative research. Her grant will fund a three-year project called “Connecting with cultural heritage: Land-based learning and healing through archeology in northern Manitoba.”

The study team will create and evaluate a land-based healing and cultural heritage program that will enable youth to explore archeological sites and artifacts reflecting the thousands of years of Inuit, Dene and Cree presence along the coast of Hudson Bay at Churchill, Man.

“We will determine if cultural heritage in land-based healing programming can contribute to wellness and leadership development of Inuit, Dene and Cree youth,” the researchers wrote.

Here’s a look at the other funded projects. More information on the studies and research teams is available here.

Dr. Harvey Max Chochinov, distinguished professor, psychiatry, Max Rady College of Medicine

Grant: $100,000 (one year)

In Chochinov’s study, health-care professionals will hold conversations with cancer patients, guided by the Patient Dignity Question: “What do I need to know about you as a person to take the best care of you possible?” The study will measure how this affects the experiences of both patients and care providers.

Dr. Ian Dixon, professor, physiology and pathophysiology, Max Rady College of Medicine; principal investigator, Institute of Cardiovascular Sciences, St. Boniface Hospital

Grant: $1,040,400 (five years)

Dixon’s project centres on proteins and processes involved in skin wound healing, with the goal of developing treatments to speed wound closure and reduce scarring. The study will investigate how age and sex affect dermal healing. It will also examine the healing of skin damage caused by chemotherapy and radiation.

Dr. Soheila Karimi, professor, physiology and pathophysiology, Max Rady College of Medicine; researcher, Children’s Hospital Research Institute of Manitoba (CHRIM)

Grant: $1,136,025 (five years)

Neural stem cell therapy has exciting potential for patients with spinal cord injury, but it currently faces the challenge that the cells die after they are transplanted. Karimi’s project will test an experimental treatment aimed at optimizing the use of neural stem cells for repairing spinal cord injury.

Dr. Jason Kindrachuk, assistant professor, medical microbiology and infectious diseases, Max Rady College of Medicine; Canada Research Chair in molecular pathogenesis of emerging viruses; researcher, CHRIM

Grant: $750,000 (five years)

Kindrachuk’s team will investigate the circulation and transmission of the monkeypox virus in wildlife in regions of Africa where the virus is endemic, as well as surrounding areas. They will also assess the potential impact of the virus on Canadian wildlife.

Dr. Lorrie Kirshenbaum, professor, physiology and pathophysiology, Max Rady College of Medicine; Canada Research Chair in molecular cardiology; director, Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre

Grant: $853,931 (five years)

Kirshenbaum’s project builds on the growing evidence of a link between body-clock disruptions – like those experienced by shift workers and people with health issues such as sleep apnea – and cardiac dysfunction. He will investigate the relationship between circadian disruption and heart attack.

Dr. Lisa Lix, professor, community health sciences, Max Rady College of Medicine; Canada Research Chair in methods for electronic health data quality

Grant: $508,725 (three and a half years)

Lix’s study focuses on using anonymized health-care databases to construct personal and family disease histories for chronic illnesses, such as heart disease. Researchers will compare two methods for creating disease histories, using data from Manitoba and Denmark, and assess their value for predicting disease risk.

Dr. Suresh Mishra, professor, internal medicine, Max Rady College of Medicine

Grant: $100,000 (one year)

Mishra will explore the role of cholesterol in the body’s production of steroid hormones. He aims to develop new ways to treat altered steroid hormone levels, which can lead to infertility and illnesses such as inflammatory diseases.

Dr. Neeloffer Mookherjee, professor, internal medicine; researcher, CHRIM

Grant: $100,000 (one year)

Mookherjee’s team will look at differences in how rheumatoid arthritis (RA) develops in males and females. In addition to using a mouse model, her team will study human samples from close relatives of RA patients, who may show changes in their blood before the appearance of clinical RA symptoms.

Dr. Christopher Pascoe, assistant professor, physiology and pathophysiology; researcher, CHRIM

Grant: $100,000 (one year)

Pascoe’s project aims to better understand how diabetes in pregnancy increases the risk of asthma in offspring. He will examine how maternal diabetes increases the twitchiness of airway smooth muscle in the lungs of offspring, and whether a specific enzyme co-ordinates changes in this muscle.

Dr. Mojgan Rastegar, professor, biochemistry and medical genetics, Max Rady College of Medicine; researcher, CHRIM

Grant: $990,675 (five years)

Rastegar has been working for more than 10 years to understand the pathobiology of Rett syndrome, a severe neurodevelopmental disorder in young children. This study will investigate the molecular and cellular abnormalities of the brain in this syndrome. The goal is to pave the way for therapeutic strategies.

Dr. Emily Rimmer, assistant professor, internal medicine, Max Rady College of Medicine

Grant: $307,530 (three years)

Rimmer’s project is a pilot study in preparation for an international randomized controlled trial of therapeutic plasma exchange as a treatment for septic shock. The researchers see potential for this treatment to save lives by removing harmful substances from the blood and replacing missing blood components.

Dr. Zulma Rueda, associate professor, medical microbiology and infectious diseases, Max Rady College of Medicine; Canada Research Chair in sexually transmitted infection – resistance and control

Grant: $100,000 (one year)

Rueda’s team will look at the incidence and impact of methamphetamine use and concurrent sexually transmitted and blood-borne infections in people living with HIV in Manitoba and Saskatchewan. One of the study’s goals is effective knowledge-sharing among people living with HIV, service providers and communities.

Dr. Geoffrey Tranmer, associate professor, College of Pharmacy

Grant: $100,000 (one year)

Tranmer will focus on edaravone, one of the few drugs approved to treat amyotrophic lateral sclerosis. In its current form, this medication has many limitations. Tranmer’s team plans to develop improved versions of edaravone and test them in order to optimize the drug and prepare it for advanced clinical trials.

Dr. Sonia Udod, associate professor, College of Nursing

Grant: $450,000 (three years)

Udod’s research will examine how health system leaders have adapted in response to the pandemic. She aims to determine how leaders can build their own and nurses’ psychological health and well-being to ensure a healthy workforce and organizational resilience at hospitals during and after the COVID-19 crisis.

Dr. Roberta Woodgate, distinguished professor, College of Nursing; Canada Research Chair in child and family engagement in health research and healthcare; researcher, CHRIM

Grant: $776,475 (five years)

Woodgate’s youth-centred, mixed-methods study aims to understand the impacts of COVID-19 on the mental health and well-being of Manitoba youth who have come of age during the pandemic. The findings will inform recommendations to improve services and supports for this population.

Grant: $100,000 (one year)

Woodgate’s team will also conduct a youth-centered, arts-based longitudinal study that will result in the creation and evaluation of a toolkit. This toolkit, co-created by youth, will be designed for use in schools to foster social connectedness and optimize youth mental health and well-being.

“These researchers are doing cutting-edge studies that will benefit individuals coping with disabilities, distress, and many serious life-threatening conditions,” says Dr. Digvir Jayas, vice-president (research and international) and Distinguished Professor, University of Manitoba. “Their work is testament to the outstanding calibre of transformational research conducted at the University of Manitoba and at our affiliated partner organizations.”

The researchers and their projects are:

Benedict Albensi

Pharmacology and Therapeutics, Max Rady College of Medicine; Investigator, St. Boniface Albrechtsen Research Centre, Children’s Hospital Research Institute of Manitoba
Project: Sex-based differences associated with mitochondrial dysfunction in Alzheimer’s disease
Funding: $725,985

Women have a higher risk of acquiring Alzheimer’s disease (AD) and it’s not known why. Differences in cellular mechanisms (genetics, metabolism), hormonal changes, and/or lifestyle factors between men and women may be at the root cause, but no one knows for sure. This study aims to bring a clearer picture into view of the biological processes underway in the onset of Alzheimer’s disease.

Michael Czubryt

Physiology and Pathophysiology, Max Rady College of Medicine; Investigator, St. Boniface Albrechtsen Research Centre
Project: Targeting scleraxis to combat cardiac fibrosis
Funding: $1,017,450

Heart disease is the primary cause of death in the western world. Cardiac fibrosis is a stiffening of the heart caused by many forms of heart disease. Fibrosis dramatically increases the risk of death and disability independently of other risk factors (up to 17 times), yet no treatments for cardiac fibrosis are available to patients. Czubryt’s laboratory has identified a protein (scleraxis) as a powerful cause of fibrosis, and initial data indicates that interfering with scleraxis can reduce fibrosis. This study will further probe this relationship in the hop of finding new treatments for fibrosis.

Ian Dixon

Physiology and Pathophysiology, Max Rady College of Medicine; Investigator, St. Boniface Albrechtsen Research Centre
Project: Ski is a negative regulator of cardiac fibrosis
Funding: $684,675

Patients surviving a heart attack or those with hypertension develop chronic heart disease. These patients make too much collagen in their heart muscle, wherein non-muscle cells called myofibroblasts secrete excessive collagens, which stiffens the heart. Most of the “glue” (extracellular matrix) between muscle cells in healthy hearts is made of tough collagen proteins. Too much collagen leads to cardiac fibrosis, which results in weak muscle contraction and relaxation. Despite this, there is currently no treatment for cardiac fibrosis, nor are there any specific cardiac drugs approved to fix cardiac fibrosis. In recent years, we have found a new protein called Ski. Ski turns off this over-deposition of matrix, in diseased heart cells. Further, we have made progress of how Ski actually achieves this positive change. We are now poised to extend our understanding of how Ski corrects cardiac fibrosis and this study aims to bring about the design new Ski-based therapies to treat cardiac fibrosis, for the prevention of heart failure.

Paul Fernyhough

Pharmacology and Therapeutics, Max Rady College of Medicine; Investigator, St. Boniface Albrechtsen Research Centre
Project: Muscarinic receptor antagonism as a novel mechanism for sensory nerve repair
Funding: $1,090,125

Objective Diabetic sensory neuropathy and chemotherapy-induced peripheral neuropathy (CIPN) are neurodegenerative diseases characterized by loss of nerve fibers in the skin. Both diseases cause significant pain and eventually lead to sensory loss. The impact of these diseases on human health is enormously damaging and there are no therapies. Recent work in Fernyhough’s lab has uncovered an endogenous signaling pathway in neurons that negatively modulates nerve fiber growth of sensory neurons. This study will enable the lab to broaden in scope and permit this therapeutic approach to be performed in a wide range of distal dying back neurodegenerative diseases.

Edward Giesbrecht

College of Rehabilitation Sciences
Project: Evaluation of a peer-led eHealth wheelchair skills training program: Training to Enhance Adaptation and Management for Wheelchair users (TEAM Wheel)
Funding: $566,099

Mobility impairment is the third most common disability; nearly 300,000 Canadians use a wheelchair or scooter because their disability makes walking difficult. Many Canadians receive their wheelchair while in hospital and must learn to contend with the social and environmental challenges of use when they return home. Because of shorter hospital stays and reduced access to outpatient rehabilitation services, wheelchair users often receive little training in how to operate and manage their mobility device. Without the appropriate skills, wheelchair users can experience health declines, diminished physical activity, and restricted participation in activities of life. The impact of reduced independence can have social and financial costs for the individual, their caregivers, and the health care system. Training to Enhance Adaptation and Management for Wheelchair users (TEAM Wheel) is a novel intervention designed to address this important transition to wheelchair use.

Tiina Kauppinen

Pharmacology and Therapeutics, Max Rady College of Medicine; Investigator, Kleysen Institute for Advanced Medicine, Health Sciences Centre and Children’s Hospital Research Institute of Manitoba
Project: Microglia and cognitive impairments in offspring exposed to gestational diabetes mellitus
Funding: $1,051,875

Maternal diabetes is the most common complication in pregnancy affecting up to 18 per cent of pregnancies. Maternal diabetes increases offspring risk for developing various health problems. Population studies have demonstrated that maternal diabetes increases offspring risk to have learning and memory deficits, and behavioral issues. Maternal diabetes is associated with elevated inflammation status, which can be detrimental for the developing brain. This study will identify the role of brain immune cells and the mechanism by how they can impair brain cells function. It will also assess whether maternal gestational diabetes differentially affects male and female offspring. The ultimate goal is to identify targets for drug development and promote healthy brain development and, thus prevent cognitive impairments in children of mothers with gestational diabetes.

Alyson Mahar

Community Health Sciences, Manitoba Centre for Health Policy, Max Rady College of Medicine
Project: Understanding cancer burden and outcomes for Canadians living with intellectual and developmental disabilities
Funding: $298,352

Not all Canadians have the same cancer risk, receive the same quality of healthcare after a cancer diagnosis, or have the same prognosis. This may be the result of many things including how much money someone has, their education, where they live, or discrimination within the healthcare system that causes people to be treated differently, regardless of how sick they are. Although cancer is a leading cause of death for Canadians living with intellectual disabilities and developmental disabilities (IDD), they may be less likely to receive high quality cancer treatment compared to other Canadians. Because people living with IDD are more likely to live in vulnerable circumstances (such as those described above), this may impact how quickly their cancer is diagnosed, their access to life-saving treatment and result in worse outcomes. The goal of this project is to determine whether or not Canadians living with IDD are more likely than Canadians who do not have IDD to be 1) diagnosed with cancer; 2) diagnosed with incurable cancer; 3) not receive the right cancer treatment; and 4) to die of their cancer. This study will highlight ways to improve the quality of care provided. We will work with our policy partners to ensure this information is usable and informative to the care of underserved cancer populations.

Brian Mark

Microbiology, Faculty of Science
Project: Development of a therapeutic modality to treat GM2 gangliosidoses
Funding: $547,740

Tay-Sachs disease and Sandhoff Disease (also knows as the GM2 gangliosidoses) are inherited neurodegenerative diseases that result from genetic mutations that inactivate an enzyme known as HexA. HexA is a protein in our cells that degrades GM2-ganglioside (GM2), a molecule found primarily on neurons of the central and peripheral nervous system. HexA degrades GM2, and if it is not active, GM2 rapidly accumulates and causes severe neurological disease.The rate of GM2 accumulation depends on how severely the genetic mutations impact HexA activity. Mark’s lab has recently engineered HexA to markedly improve its stability and function for enzyme replacement therapy. This study will use the engineered enzyme, known as HexM, to develop an enzyme replacement therapy that will be evaluated in models of GM2 gangliosidosis in combination with a drug known to rescue residual HexA activity in cells. The approach holds promise to reduce GM2 accumulation and reverse the progression of this debilitating family of neurological diseases.

Aaron Marshall

Immunology, Max Rady College of Medicine
Project: Control of B cell metabolism by the PI3K pathway: applications for autoimmunity
Funding: $956,250

The immune system is critical to human health. In order to develop vaccines and treatments for diseases where the immune system malfunctions (such as autoimmunity, inflammatory diseases or immunodeficiency), we need to better understand the fundamental mechanisms governing immune responses. Our research deals with the arm of the immune system responsible for producing antibodies, which are specialized proteins that bind to microorganisms and target them for destruction by the immune system. Antibodies are secreted into the blood and mucosal surfaces by cells called B lymphocytes. This study aims to define the molecular signaling pathways that regulate the activities of B lymphocytes during normal immune responses or abnormal autoimmune responses. The work is identifying new molecular pathways that can be targeted to shut down B cells and treat autoimmune disease.

Kirk McManus

Biochemistry and Medical Genetics, Max Rady College of Medicine; Investigator, Research Institute of Oncology and Hematology, a joint institute of the University of Manitoba and CancerCare Manitoba
Project: Exploring and Exploiting Reduced USP22 Expression in Colorectal Cancer
Funding: $807,075

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in Canada, and although advances in treatment options have improved the overall survival for early stage CRCs, about 50 per cent of individuals are still diagnosed with late stage disease that is often incurable. The development of highly specific, anti-cancer treatments is a significant research challenge; however, recent efforts suggest that exploiting the mutated genes and abnormal pathways that drive cancer development may hold tremendous clinical potential. Accordingly, greater insight into the mutated genes and abnormal pathways driving CRC formation is needed so that new treatment strategies and drug options can be developed that exploit them. McManus’s lab will build on its past discoveries to identify novel drug targets and lead chemotherapeutics that will be tested in pre-clinical studies to ideally and ultimately deliver new therapeutic options to individuals diagnosed with CRC.

Leslie L. Roos and Marni Brownell

Community Health Sciences, Manitoba Centre for Health Policy, Max Rady College of Medicine; Investigator, Children’s Hospital Research Institute of Manitoba
Project: Health, Well-Being, and Disease-Birth to Adulthood in Manitoba
Funding: $244,799

Why are some children healthy and others not? Why do some children perform well in school and others drop out? Why are some youths arrested while others never come near the justice system? The population-based Manitoba data enable research on the consequences of birth, childhood, and adolescent experiences for health and well-being over the first 20 years. This study will explore the degree to which predictors of poor young adult outcomes occur early enough to allow the possibility of intervention. Roos’s lab will analyze Manitoba’s data on several government projects designed to improve children’s wellbeing.

Frank Schweizer

Chemistry, Faculty of Science; Medical Microbiology, Max Rady College of Medicine
Project: Preclinical studies on aminoglycoside-derived antibiotic adjuvants (AGDAAs)
Funding: $646,425

According to the United Nations (UN) and the World Health Organization (WHO) antimicrobial resistance (AMR) is one the largest threats to public health and economic growth. Recently, the WHO for the first time divided pathogens into three categories according to the urgency of need for new antibiotics: critical, high and medium priority. The most critical group of all includes multidrug resistant bacteria that pose a particular threat in hospitals, nursing homes, and among patients whose care requires devices such as ventilators and blood catheters. To overcome the bottleneck in antibacterial drug discovery, this study aims to develop helper molecules (adjuvants) designed to enhance membrane permeability, reduce efflux of antibiotics and prevent or delay resistance development against these pathogens. The overall goal of this proposal is to identify optimized helper molecules capable of rescuing antibiotics from resistance in animal models of infection against multidrug-resistant priority pathogens and to understand their mode of actions.

Kellie Thiessen and Katherine Whitecloud (Assembly of First Nations)

College of Nursing and Children’s Hospital Research Institute of Manitoba; and
Project: Welcoming the ‘Sacred Spirit’ (child): Connecting Indigenous and Western ‘ways of knowing’ to inform future policy partnerships to optimize maternal child health service delivery initiatives in remote Canadian regions
Funding: $810,901

Ongoing and historical colonial health practices have systematically diminished the health and well-being of Indigenous communities. One critically important primary healthcare service that shows the impact of colonial relations is maternal/child healthcare. There is the “absence of teachings regarding the ‘Sacred Spirit’ (child) along with the responsibilities and preparation for ‘life-giving’ across the childbearing continuum (preconception, pregnancy, birth and post-delivery). Strategies to embrace and include Indigenous knowledge, values, teachings, and stories are essential for a healthy life in Indigenous communities; the absence of these strategies disrupts the relations among youth, young parents, families, and communities. In this study, we explore maternal healthcare delivery systems and services across 4 remote Canadian jurisdictions. Our exploration includes Indigenous and Western world views and aims to improve the health of communities by bringing back the ‘Sacred Spirit’ [child]. The teaching tells us that achieving this equates to maintaining wellness. We have and will continue to actively engage Indigenous and non-Indigenous members in 4 remote Canadian jurisdictions each involved in delivering or receiving maternal care. Data sources include interviews, focus groups [story-telling], and document analysis. The outcome will be identification of maternity care delivery models that are integrated, cost-efficient, culturally appropriate, and effectively supporting persons to maintain health and wellness within their own community.

Roberta Woodgate

Canada Research Chair in Child and Family Engagement in Health Research and Healthcare, College of Nursing; Investigator, Children’s Hospital Research Institute of Manitoba and St. Boniface Albrechtsen Research Centre
Project 1: Designing a Responsive and Integrative Model of Respite Care for Families of Children with Complex Care Needs and Conditions (CCNC) through Patient-Oriented Research
Funding: $458,999

Children with complex care needs and conditions (CCNC) are those with chronic physical and developmental disabilities who require multiple services. Caring for children with CCNC is an immense undertaking for families that involves constantly coordinating multiple needs and services in a complex system with limited supports. As such, family well-being can be greatly impacted. The goal of this study is to provide evidence to inform the design of a new model of respite care that can respond to the diverse and changing needs of families of children with CCNC in Manitoba (MB).

Project 2: Non-suicidal self-injury among youth: Perspectives of youth who self-harm, their families and service providers
Funding: $539,324

Self-harm among youth is a major public health concern. Usually first occurring in early adolescence, it is estimated that 18 per cent of youth engage in self-harming behaviours at some point in their lives. These may include cutting, self-hitting, pinching, scratching, burning, minor overdosing and interfering with wound healing. Recent media reports reinforce that self-harming provokes a great deal of suffering among youth and their families, who struggle to access appropriate care. Likewise, service providers find it difficult to treat youth who self-harm. While self-harming can have a significant impact on a youth’s life, it is poorly understood. Before we can develop effective services and supports, we first need to gain an understanding of self-harm from the perspectives of youth who self-harm and their families as well as service providers who support them. The aim of this study is to increase our understanding of the experiences and needs of youth who self-harm and their families. This information is essential in order to design better services and supports for this population.